Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C1-produced ferritin nanoparticle Mpox antigen vaccine
- Development stage
- Preclinical
- Lead developer
- Virovax Bio
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The C1-produced ferritin nanoparticle Mpox antigen vaccine is a recombinant protein subunit vaccine candidate developed through a collaboration between Dyadic International and ViroVax. The vaccine utilizes Dyadic's proprietary C1 protein production platform, derived from the fungus *Thermothelomyces heterothallica*, to express Mpox virus antigens. These antigens are engineered to self-assemble onto a ferritin nanoparticle scaffold, a design intended to enhance immunogenicity by presenting the antigens in a multivalent format. The vaccine is formulated with ViroVax's adjuvant technology to further boost the immune response. The program aims to provide a scalable, cost-effective alternative to existing Mpox vaccines for both human and veterinary applications.
- Other names
- Dyadic Mpox vaccineViroVax Mpox vaccineC1-cell-produced Mpox vaccineC-1-cell-produced Mpox vaccineC 1-cell-produced Mpox vaccine
Beyond the preview
Go deeper on C1-produced ferritin nanoparticle Mpox antigen vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C1-produced ferritin nanoparticle Mpox antigen vaccine.